bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for …
Piper Jeffery analyst Joshua Schimmer is weighing in on the biotechnology company bluebird bio Inc (NASDAQ:BLUE) and French genome engineering company Cellectis SA (ADR) (NASDAQ:CLLS), as shares …
bluebird bio Inc (NASDAQ:BLUE) plummeted more than 30% this morning down to $58 as the company presented disappointing BB305 data at the American …
bluebird bio Inc (NASDAQ:BLUE) and ViroMed Co., Ltd.
Piper Jaffray’s healthcare analyst Joshua Schimmer came out today with a few insights on the pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) and clinical-stage biotechnology company bluebird bio …
Goldman Sachs analyst Salveen Richter came out today with new ratings and price targets on a handful of biotechnology stocks. Lets take a look and see what Richter …
As always, it’s been a busy week in the biotechnology sector. Analysts remain bullish on both bluebird bio Inc (NASDAQ:BLUE) on the back …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, announced …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, today …
Analysts are weighing in on biotech companies bluebird bio Inc (NASDAQ:BLUE) and Agios Pharmaceuticals Inc. (NASDAQ:AGIO), with mixed ratings.
